FORA Capital’s Neurocrine Biosciences NBIX Stock Holding History

FORA Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$548K	Buy	+4,157	New	+$552K	0.04%	299
2024 Q4	–	Sell	-16,752	Closed	-$1.93M	–	526
2024 Q3	$1.93M	Buy	+16,752	New	+$2.3M	0.23%	133
2023 Q3	–	Sell	-2,298	Closed	-$217K	–	542
2023 Q2	$217K	Sell	2,298 -7,367	-76%	-$720K	0.03%	316
2023 Q1	$978K	Buy	+9,665	New	+$1.01M	0.1%	249
2022 Q4	–	Sell	-8,272	Closed	-$879K	–	601
2022 Q3	$879K	Buy	+8,272	New	+$839K	0.17%	183
2021 Q3	–	Sell	-2,863	Closed	-$279K	–	684
2021 Q2	$279K	Sell	2,863 -258	-8%	-$24.7K	0.05%	367
2021 Q1	$304K	Buy	+3,121	New	+$327K	0.1%	227
2020 Q4	–	Sell	-2,204	Closed	-$212K	–	1060
2020 Q3	$212K	Sell	2,204 -3,341	-60%	-$386K	0.14%	166
2020 Q2	$676K	Buy	+5,545	New	+$613K	0.23%	118
2020 Q1	–	Sell	-8,281	Closed	-$890K	–	1226
2019 Q4	$890K	Buy	+8,281	New	+$867K	0.09%	274

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FORA Capital's NBIX Position: Q1 2026 in Review

FORA Capital opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 4,157 shares worth $548K. The stake represents 0.04% of the portfolio and ranks #299 among its holdings. This is a return to the name: FORA Capital previously reported a position in NBIX as recently as Q3 2024.

FORA Capital first reported a position in NBIX in Q4 2019 and has held it in 10 quarters since. The position peaked at $1.93M in Q3 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

FORA Capital held 4,157 shares of Neurocrine Biosciences worth $548K as of Q1 2026.
Neurocrine Biosciences was a new FORA Capital position in Q1 2026.
Neurocrine Biosciences made up 0.04% of FORA Capital's portfolio in Q1 2026, its #299 holding.
FORA Capital first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 10 quarters since.
FORA Capital's Neurocrine Biosciences position peaked at $1.93M in Q3 2024.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.